 Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting AGM to shareholders the Notice, which can be viewed and downloaded from The Notice states that the AGM is scheduled to be held at Autolus headquarters in White City at 1.00 pm BST 8.00 am EDT on Thursday, June 18, 2020. In order to ensure that our AGM may proceed on Thursday, June 18, 2020 in compliance with the Stay at Home Measures, arrangements have been made for a quorum of two shareholders only to be present at our AGM this year. 